Drug Trial Radar · NCT07790523
Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
410,000
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
May 31, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Tor Biering-SørensenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ModernaTX, Inc.
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza vaccine/Efluelda® and mRNA-1273/Spikevax®) among adults aged 65 years and older.
Conditions
- COVID-19
- Influenza
Interventions
mCombriax® (mRNA-1083)Biological
An authorized mRNA-based multicomponent vaccine encoding antigens targeting both seasonal influenza and SARS-CoV-2 viruses.
Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)Biological
Same-day co-administration of an authorized high-dose trivalent influenza vaccine (TIV-HD; Efluelda®) and an authorized COVID-19 mRNA vaccine (Spikevax®, mRNA-1273)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Medically attended influenza and/or COVID-19Time frame: From Day 14 after vaccination through the end of follow-up, up to 8 months after vaccination
- Influenza and/or COVID-19 hospitalizationTime frame: From Day 14 after vaccination through the end of follow-up, up to 8 months after vaccination
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte
Hellerup, Denmark
Danske Lægers Vaccinations Service
Søborg, Denmark
General Public Health Directorate of Galician Health Service
Santiago de Compostela, A Coruña, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.